BLI Berkeley Lights

Berkeley Lights Announces Pricing of Public Offering by Selling Stockholders

Berkeley Lights Announces Pricing of Public Offering by Selling Stockholders

EMERYVILLE, Calif., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc., a leader in Digital Cell Biology, today announced the pricing of its previously announced public offering of 3,000,000 shares of common stock to be sold by certain selling stockholders of Berkeley Lights at a public offering price of $86.00 per share. In addition, the selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 450,000 shares of common stock. The offering is expected to close on or about November 23, 2020, subject to the satisfaction of customary closing conditions. The selling stockholders will receive all of the net proceeds from the offering. Berkeley Lights will not receive any proceeds from the offering.

J.P. Morgan, Morgan Stanley and Cowen are acting as lead book-running managers for the offering.

A registration statement relating to the shares being sold in this offering by the selling stockholders has been filed with the Securities and Exchange Commission and was declared effective on November 18, 2020. The offering is being made only by means of a prospectus, copies of which may be obtained, when available, from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, via telephone: +1 (866) 803-9204, or by emailing ; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; and Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, via telephone: +1 (833) 297-2926, or by emailing .

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Berkeley Lights

Berkeley Lights is a leading Digital Cell Biology company focused on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products for our customers. The Berkeley Lights Platform captures deep phenotypic, functional and genotypic information for thousands of single cells in parallel and can also deliver the live biology customers desire in the form of the best cells. Our platform is a fully integrated, end-to-end solution, comprising proprietary consumables, including our OptoSelect chips and reagent kits, advanced automation systems, and application software. We developed the Berkeley Lights Platform to provide the most advanced environment for rapid functional characterization of single cells at scale, the goal of which is to establish an industry standard for our customers throughout their cell-based product value chain.

Berkeley Lights’ Beacon and Lightning systems and Culture Station instrument are For Research Use Only. Not for use in diagnostic procedures.

Forward-Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Berkeley Lights, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding completion of the public offering that involve risks and uncertainties, including, without limitation, risks and uncertainties related to market conditions and the satisfaction of closing conditions related to the public offering. Such forward-looking statements involve substantial risks and uncertainties that relate to future events and the actual results could differ significantly from those expressed or implied by the forward-looking statements. Berkeley Lights undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties relating to the business of the Company in general, see the preliminary prospectus for this offering included as part of the Registration Statement on Form S-1 related to the offering filed with the SEC, and its future periodic reports to be filed with the SEC.

Press Contact

Investor Contact



EN
19/11/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Berkeley Lights

 PRESS RELEASE

Berkeley Lights to Participate at the 27th European Society for Animal...

Berkeley Lights to Participate at the 27th European Society for Animal Cell Technology Meeting Lonza and Edinburgh Genome Foundry to present their high-throughput single-cell screening workflow use cases using the Beacon® Platform EMERYVILLE, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, today announced its participation at the 27th Annual European Society for Animal Cell Technology (ESCAT), being held from June 26 - 29, 2022 at the Lisbon Congress Centre in Lisbon, Portugal. This year’s conference, with the motto, “Adv...

 PRESS RELEASE

Berkeley Lights Reports First Quarter 2022 Financial Results

Berkeley Lights Reports First Quarter 2022 Financial Results EMERYVILLE, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, today reported financial results for the quarter ended March 31, 2022. Recent Highlights Delivered total revenue of $20.2 million for the first quarter of 2022, representing growth of 8.5% year over yearSigned a strategic partnership agreement with Vestaron to develop pesticidal peptides using the Company’s Beacon® platform and proprietary high-throughput, functional screening service Released an upgrade ...

 PRESS RELEASE

Berkeley Lights to Participate in the 18th Annual PEGS Boston Conferen...

Berkeley Lights to Participate in the 18th Annual PEGS Boston Conference & Expo Company’s latest data to be presented on “Rapid High-Throughput Workflow for TCR Discovery on Solid Tumors with Functional Verification” EMERYVILLE, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, today announced its participation at the 18th Annual PEGS Boston Conference, a protein engineering and cell therapy summit, being held virtually and in person from May 2-6, 2022 at the Hynes Convention Center. Berkeley Lights’ participation this year...

 PRESS RELEASE

Berkeley Lights to Report First Quarter 2022 Financial Results on May ...

Berkeley Lights to Report First Quarter 2022 Financial Results on May 9, 2022  EMERYVILLE, Calif., April 26, 2022 (GLOBE NEWSWIRE) --  Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, today announced that the Company will be reporting financial results for the first quarter 2022 after market on Monday, May 9, 2022. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.   Live audio of the webcast will be available on the “Investors” section of the Company’s website at The webcast will be a...

 PRESS RELEASE

Berkeley Lights Announces Appointment of Lucas S. Vitale as Chief Huma...

Berkeley Lights Announces Appointment of Lucas S. Vitale as Chief Human Resources Officer EMERYVILLE, Calif., April 13, 2022 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, announced the appointment of Lucas Vitale to the newly created role of Chief Human Resources Officer (“CHRO”), effective immediately. Vitale will lead Berkeley Lights' Human Resources function. He will report directly to the Company’s Chief Executive Officer (CEO), Dr. Siddhartha Kadia. As Berkeley Lights’ newly appointed CEO, Dr. Kadia is focused on the further development of...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch